Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.82 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.81 |
| ▸ | MTOR | P42345 | 2/20 | 0.81 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.70 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.70 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.70 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.70 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.70 |
| ▸ | CHUK | O15111 | 1/20 | 0.70 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.70 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.70 |
| ▸ | RAF1 | P04049 | 1/20 | 0.70 |
| ▸ | BRAF | P15056 | 1/20 | 0.70 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.70 |
| ▸ | JAK1 | P23458 | 1/20 | 0.70 |
| ▸ | TYK2 | P29597 | 1/20 | 0.70 |
| ▸ | FLT3 | P36888 | 1/20 | 0.70 |
| ▸ | CLK1 | P49759 | 1/20 | 0.70 |
| ▸ | CLK2 | P49760 | 1/20 | 0.70 |
| ▸ | CLK3 | P49761 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10092297 | 0.90 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CBPIK3CG | |
| SCHEMBL13976099 | 0.89 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CBPIK3CG | |
| SCHEMBL30538318 | 0.89 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CBPIK3CG | |
| SCHEMBL10112594 | 0.89 | PIK3CA (0.98) | PIK3CAPIK3R1MTORPIK3CBPIK3CG | |
| SCHEMBL1308641 | 0.89 | PIK3CA (0.74) | PIK3CAPIK3R1MTORPIK3CBPIK3CG | |
| SCHEMBL31038234 | 0.89 | PIK3CA (0.98) | PIK3CAPIK3R1MTORPIK3CBPIK3CG | |
| Hydrochloric Acid SCHEMBL29370622 | 0.88 | PIK3CA (1.00) | PIK3CAPIK3R1MTORPIK3CBPIK3CG | |
| SCHEMBL1309436 | 0.88 | PIK3CA (0.77) | PIK3CAPIK3R1MTORPIK3CBPIK3CG | |
| SCHEMBL10092298 | 0.87 | PIK3CA (0.81) | PIK3CAPIK3R1MTORPIK3CBPIK3CG | |
| SCHEMBL1310000 | 0.85 | PIK3CA (0.82) | PIK3CAPIK3R1MTORPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1277738-B1 | CONDENSED HETEROARYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2011-03-30 | — | — | EP | claimed |
| US-6608053-B2 | Phosphatidylinositol 3-kinase (PI3K) inhibitors/anticancer agents such as N-(2-(3-benzenesulfonylaminophenyl)-4-morphoniloquinazolin-6-yl)acetamide | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | claimed |
| EP-1277738-A1 | CONDENSED HETEROARYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-22 | — | — | EP | claimed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2020-02-04 | — | — | US | disclosed |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2019-03-14 | — | — | US | disclosed |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2018-09-13 | — | — | US | disclosed |
| US-9993460-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2018-06-12 | — | — | US | disclosed |
| US-20050014771-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2005-01-20 | — | — | US | disclosed |
| US-6838457-B2 | Fused heteroaryl derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| US-6770641-B2 | Fused heteroaryl derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| US-20040009978-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2004-01-15 | — | — | US | disclosed |
| US-20030236271-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6608056-B1 | Phosphatidylinositol 3-kinase inhibitors and carcinostatic agents | YAMANOUCHI PHARMACEUTICAL CO., LTD (JP) | 2003-08-19 | — | — | US | disclosed |
| US-6608053-B2 | Phosphatidylinositol 3-kinase (PI3K) inhibitors/anticancer agents such as N-(2-(3-benzenesulfonylaminophenyl)-4-morphoniloquinazolin-6-yl)acetamide | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1277738-A1 | CONDENSED HETEROARYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-20020151544-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236271-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | PIK3CA 7/4885PIK3R1 4/4885MTOR 27/4885 |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | PIK3CA 1228/4885PIK3R1 1490/4885MTOR 2086/4885 |
| US-20040009978-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | PIK3CA 7/4885PIK3R1 4/4885MTOR 27/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | PIK3CA 426/4885PIK3R1 1201/4885MTOR 2949/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | PIK3CA 1228/4885PIK3R1 1490/4885MTOR 2086/4885 |
| US-20020151544-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | PIK3CA 7/4885PIK3R1 4/4885MTOR 27/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | PIK3CA 426/4885PIK3R1 1201/4885MTOR 2949/4885 |
| US-20050014771-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | PIK3CA 7/4885PIK3R1 4/4885MTOR 27/4885 |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, CYP11B2 | PIK3CA 1050/4885PIK3R1 1911/4885MTOR 2890/4885 |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | PIK3CA 1228/4885PIK3R1 1490/4885MTOR 2086/4885 |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, CYP11B2 | PIK3CA 1050/4885PIK3R1 1911/4885MTOR 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.